Introduction: Initial continuous intravenous (CIV) tacrolimus (0.03 mg/kg/day based on ideal body weight [IBW]) has been favored for graft versus host disease (GVHD) prevention in allogeneic stem cell transplant patients due to the consistent, steady-state degree of immunosuppression; however, this method poses many logistical challenges. We implemented intermittent (IIV) tacrolimus at a starting dose of 0.015 mg/kg IBW twice daily over 4 h. To our knowledge this is the first retrospective comparison of CIV to IIV tacrolimus.
Objectives: The primary objective was to evaluate the safety of IIV tacrolimus in comparison to CIV with respect to nephrotoxicity and neurotoxicity. The secondary objectives were to compare the incidence of grade II-IV acute GVHD (aGVHD) and chronic GVHD (cGVHD) at day +180, outcomes including relapse and overall survival, cell engraftment, and reactivation of cytomegalovirus and Epstein-Barr virus.
Methods: This retrospective, single-center review evaluated adults who received an allogeneic stem cell transplant patients between January 1, 2020, and December 31, 2022.
Results: Fifty-one unique patients were eligible for evaluation – 28 in the IIV cohort and 23 in the CIV group. The number of patients who developed nephrotoxicity and neurotoxicity were comparable between groups with no significant differences noted. No severe neurotoxicity was identified in either population. Secondary objectives revealed no significant difference in GVHD incidence or survival outcomes.
Conclusion: IIV tacrolimus is comparable to CIV in terms of safety while also maintaining similar outcomes at day +180. IIV is a safe and feasible alternative to CIV in adult allogeneic stem cell transplant recipients.
PrzepiorkaDDevineSFayJ, et al.Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant1999; 24: 1053–1056.
2.
BautersTRaynerPTherrienR, et al.Practical considerations in the use of intravenous tacrolimus in hematopoietic stem cell transplantation patients. J Oncol Pharm Pract2015; 21: 478–480.
3.
BacopoulosAJHoLYangA, et al.Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit. J Oncol Pharm Pract2021; 27: 33–39.
4.
HashmiHBhandariSKumarR, et al.Twice-daily intravenous bolus tacrolimus infusion: a safe and effective regimen for graft-versus-host disease prophylaxis. Hematol Oncol Stem Cell Ther2020; 13: 232–237.
5.
SkeensMPaiVGareeA, et al.Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. Bone Marrow Transplant2012; 47: 1415–1418.
6.
HayekFNAl-GhawiHAllenJ, et al.Twice-daily intravenous bolus tacrolimus infusion for acute graft-vs-host disease prophylaxis. Biol Blood Marrow Transplant2005; 11: 45.
7.
McCuneJSBemerMJ. Pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressants in allogeneic haematopoietic cell transplantation: part I. Clin Pharmacokinet2016; 55: 525–550.
8.
WingardJRNashRAPrzepiorkaD, et al.Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant1998; 4: 157–163.
9.
PrzepiorkaDNashRAWingardJR, et al.Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant1999; 5: 94–97.
NakamuraYTakeuchiHOkuyamaK, et al.Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. Transplant Proc2005; 37: 1725–1727.
12.
MyersALZhangYKawediaJD, et al.Stability of tacrolimus injection diluted in 0.9% sodium chloride injection and stored in Excel bags. Am J Health Syst Pharm2016; 73: 2083–2088.
